FAKTOR OPTIONSSCHEIN - MODERNA | Delayed Deutsche Boerse AG 08:50:31 2024-07-11 am EDT | ||
| 6.89 EUR | +5.03% |
|
| Current month | -5.61% | ||
| 1 month | -54.35% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
| Date | Price | Change |
|---|---|---|
| 24-07-11 | 6.89 | +5.03% |
| 24-07-10 | 6.56 | +2.98% |
| 24-07-09 | 6.37 | 0.00% |
| 24-07-08 | 6.37 | -5.77% |
| 24-07-05 | 6.76 | -0.88% |
Delayed Quote Deutsche Boerse AG
Last update July 11, 2024 at 08:50 am EDT
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | MODERNA, INC. |
| Issuer | 
BNP Paribas
|
| WKN | PC3MRN |
| ISIN | DE000PC3MRN4 |
| Date issued | 2022-09-29 |
| Strike | 117.4 $ |
| Maturity | Unlimited |
| Parity | 1 : 1 |
| Emission price | 50 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 179.6 € |
|---|---|
| Lowest since issue | 2.16 € |
| Spread | 0.04 € |
| Spread % | 0.58% |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
24
Last Close Price
117.4
USD
Average target price
145.9
USD
Spread / Average Target
+24.19%
- Stock Market
- Certificates
- Certificat
